With recent advances in molecular and genomic investigations, the impact of hepatitis B viral and host factors on the progression of chronic HBV infection has been explored. For viral factors, hepatitis B viral load is a strong predictor for liver disease progression. Hepatitis B viral kinetics appear to be important for successful anti-viral therapy. Serum HBsAg level serves as a complementary marker to viral load for the prediction of HBV-related adverse outcomes in patients with low viral load. In those with low viral load, high serum HBsAg level is associated with higher risks of cirrhosis and HCC. Hepatitis B core-related antigen (HBcrAg) induces host immune responses, and the reduction of the HBcrAg level as well as the increment of total anti-HBc level are significantly associated with favorable outcomes. HBV genotypes (genotype C/D) and mutants (basal core promoter and deletion mutation in pre-S genes) are well known viral genetic markers to predict disease progression. For host factors, serum inflammatory biomarkers have been developed to evaluate the HBV-associated hepatic necroinflammation and fibrosis. Host single nucleotide polymorphism on sodium taurocholate cotransporting polypeptide (NTCP, an HBV entry receptor) may be associated with a decreased risk for cirrhosis and HCC. In conclusion, patients with chronic hepatitis B should be evaluated with relevant viral and host markers to identify those who are at a higher risk of liver disease progression and then receive timely antiviral therapy.
Citations
Citations to this article as recorded by
Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection Clémence Boivin‐Champeaux, Nieves Velez de Mendizabal, Aksana Jones, Scott Balsitis, Stephan Schmidt, Justin S. Feigelman, Francine Johansson Azeredo CPT: Pharmacometrics & Systems Pharmacology.2025; 14(3): 420. CrossRef
Bepirovirsen for the treatment of chronic hepatitis B infection Hyun Young Woo, Jeong Heo Future Virology.2025; 20(6-7): 227. CrossRef
Global strategies and actions to eliminate hepatitis B virus infection Chih-Lin Lin, Jia-Horng Kao Clinical and Molecular Hepatology.2025; 31(4): 1197. CrossRef
Hepatitis B viral load and its association with liver function in chronic hepatitis B virus-positive patients – A retrospective study Lakshmi Nandakumar, Sunil S Shivekar, Mathan Kumar, N.S.K Roobhini Sri, Mangaiyarkarasi Thiyagarajan, R Udhaya Sankar, Gopal Rangasamy, Rajalakshmi Mahendran Journal of Current Research in Scientific Medicine.2025; 11(2): 110. CrossRef
Associations of hepatitis B and C in women aged 15–49 years with neonatal preterm birth in 66 high‐income countries, 1990–2019 Guiying Cao, Jue Liu, Min Liu International Journal of Gynecology & Obstetrics.2024; 164(1): 115. CrossRef
Precision Management of Patients with HBV Infection Chih-Lin Lin, Jia-Horng Kao Current Hepatology Reports.2024; 23(1): 22. CrossRef
Latest insights into the epidemiology, characteristics, and therapeutic strategies of chronic hepatitis B patients in indeterminate phase Junye Liu, Yan Yu, Heping Zhao, Lei Guo, Wenjuan Yang, Yuzhu Yan, Jing Lv European Journal of Medical Research.2024;[Epub] CrossRef
Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals Soo Young Hwang, Sung Hwan Yoo, Hye Young Chang, Sora Kim, Jung Il Lee, Kwan Sik Lee, Young Youn Cho, Kim Hyung Joon, Hyun Woong Lee Journal of Viral Hepatitis.2023; 30(1): 39. CrossRef
Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection Chih-Lin Lin, Jia-Horng Kao Clinical and Molecular Hepatology.2023; 29(3): 605. CrossRef
Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma Diren Arda Karaoglu, Meral Uner, Cem Simsek, Ali Osmay Gure, Secil Demirkol-Canli Biology.2023; 12(2): 188. CrossRef
Hepatitis B doubly spliced protein (HBDSP) promotes hepatocellular carcinoma cell apoptosis via ETS1/GATA2/YY1-mediated p53 transcription Xiazhen Xu, Lu Zhang, Guiying Ye, Jiajian Shi, Yibin Peng, Fan Xin, Yi Lin, Qiong Wu, Xu Lin, Wannan Chen, J.-H. James Ou Journal of Virology.2023;[Epub] CrossRef
Occult Hepatitis B virus (HBV) infection and challenges for hepatitis elimination: A literature review Nathália Alves Araujo de Almeida, Vanessa Salete de Paula Journal of Applied Microbiology.2022; 132(3): 1616. CrossRef
Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma Mi Na Kim, Beom Kyung Kim, Yun Ho Roh, Na Ryung Choi, Su Jong Yu, Seung Up Kim Clinical Gastroenterology and Hepatology.2022; 20(8): 1877. CrossRef
Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B Won-Mook Choi, Gi-Ae Kim, Jonggi Choi, Seungbong Han, Young-Suk Lim Journal of Clinical Investigation.2022;[Epub] CrossRef
Correlations between serum hepatitis B core-related antigen and hepatitis B surface antigen in patients with hepatitis B cirrhosis and a hepatitis B virus-DNA-negative status: a retrospective study Baiguo Xu, Anjing Liu, Ying Liu, Tao Han, Hua Guo, Xian Ding, Huiling Xiang Journal of International Medical Research.2022;[Epub] CrossRef
Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B Issam Tout, Pietro Lampertico, Thomas Berg, Tarik Asselah Antiviral Research.2021; 185: 104992. CrossRef
Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management Alicia Vachon, Carla Osiowy Viruses.2021; 13(6): 951. CrossRef
Editorial: HBV cure—the quest for biomarkers to predict off‐treatment sustained response Vincent Thibault, Tarik Asselah Alimentary Pharmacology & Therapeutics.2021; 53(4): 552. CrossRef
Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi Ian Baudi, Takako Inoue, Yasuhito Tanaka International Journal of Molecular Sciences.2020; 21(3): 949. CrossRef
Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase Hye Won Lee, Eun Hwa Kim, Jinae Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim Clinical and Translational Gastroenterology.2020; 11(3): e00140. CrossRef
An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well‐controlled viremia Hye W. Lee, Soo Y. Park, Myeongjee Lee, Eun J. Lee, Jinae Lee, Seung U. Kim, Jun Y. Park, Do Y. Kim, Sang H. Ahn, Beom K. Kim Liver International.2020; 40(7): 1736. CrossRef
Association of Hepatitis B Core-Related Antigen and Antihepatitis B Core Antibody With Liver Fibrosis Evolution in Human Immunodeficiency Virus-Hepatitis B Virus Coinfected Patients During Treatment With Tenofovir Romuald Cruchet, Lorenza N C Dezanet, Sarah Maylin, Audrey Gabassi, Hayette Rougier, Patrick Miailhes, Caroline Lascoux-Combe, Julie Chas, Pierre-Marie Girard, Constance Delaugerre, Karine Lacombe, Anders Boyd Open Forum Infectious Diseases.2020;[Epub] CrossRef
Evaluation of HBV serological markers in treatment-naïve HBV mono-infected patients and HBV-HIV co-infected patients Bei Jiang, Rui Su, Doudou Ren, Xiaoya Zheng, Yu Cao, Yuqiang Mi, Fengmei Wang, Ping Ma Virus Research.2020; 290: 198117. CrossRef
Biomarkers for hepatitis B virus replication: an overview and a look to the future Feng-Cai Li, Yue-Kai Li, Yu-Chen Fan Expert Review of Gastroenterology & Hepatology.2020; 14(12): 1131. CrossRef
Quantification of Antibody to Hepatitis B Core Antigen to Predict Outcomes of Patients With HBV Infection Young-Suk Lim Clinical Gastroenterology and Hepatology.2019; 17(1): 39. CrossRef
Fibrosis‐matched outcomes between chronic hepatitis B patients with drug‐induced virological response and inactive carriers Hye Soo Kim, Oidov Baatarkhuu, Hye Won Lee, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kijun Song, Kwang‐Hyub Han, Beom Kyung Kim, Seung Up Kim Liver International.2019; 39(1): 81. CrossRef
Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy Meng-Lan Wang, Rong Deng, En-Qiang Chen, Chuan-Min Tao, Juan Liao, Tao-You Zhou, Juan Wang, Hong Tang Clinics and Research in Hepatology and Gastroenterology.2019; 43(3): 301. CrossRef
Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers Nishi H. Patel, Shivali S. Joshi, Keith C.K. Lau, Eliana Castillo, Carla S. Coffin Journal of Clinical Virology.2019; 111: 42. CrossRef
Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA En‐Qiang Chen, Meng‐Lan Wang, Ya‐Chao Tao, Dong‐Bo Wu, Juan Liao, Min He, Hong Tang Journal of Viral Hepatitis.2019; 26(5): 586. CrossRef
Establishment of an analysis model based on measurement of hepatitis B viral infection serum markers Yang Guang, Li Yuzhong, Liu Hui BMC Infectious Diseases.2019;[Epub] CrossRef
Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals Hye Won Lee, Seung Up Kim, Oidov Baatarkhuu, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim Scientific Reports.2019;[Epub] CrossRef
High risk of clinical events in untreated HBeAg‐negative chronic hepatitis B patients with high viral load and no significant ALT elevation Gwang Hyeon Choi, Gi‐Ae Kim, Jonggi Choi, Seungbong Han, Young‐Suk Lim Alimentary Pharmacology & Therapeutics.2019; 50(2): 215. CrossRef
External validation of the modified PAGE‐B score in Asian chronic hepatitis B patients receiving antiviral therapy Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Beom Kyung Kim Liver International.2019; 39(9): 1624. CrossRef
The Role of Hepatitis B Core-Related Antigen Takako Inoue, Yasuhito Tanaka Genes.2019; 10(5): 357. CrossRef
Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals Hye Won Lee, Seung Up Kim, Jun Yong Park, Oidov Baatarkhuu, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Beom Kyung Kim Clinical and Translational Gastroenterology.2019; 10(6): e00036. CrossRef
Roadmap to functional cure of chronic hepatitis B: An expert consensus Qin Ning, Di Wu, Gui-Qiang Wang, Hong Ren, Zhi-Liang Gao, Peng Hu, Mei-Fang Han, Yan Wang, Wen-Hong Zhang, Feng-Min Lu, Fu‐Sheng Wang Journal of Viral Hepatitis.2019; 26(10): 1146. CrossRef
Zeaxanthin Dipalmitate in the Treatment of Liver Disease Nisma Lena Bahaji Azami, Mingyu Sun Evidence-Based Complementary and Alternative Medicine.2019; 2019: 1. CrossRef
The epidemiology of hepatitis B virus infection in Korea Sun Young Yim, Ji Hoon Kim The Korean Journal of Internal Medicine.2019; 34(5): 945. CrossRef
Hepatitis B and Delta: clinical aspects of patients in the Brazilian Western Amazonia Marcelo Siqueira de Oliveira, Romeu Paulo Martins Silva, Suiane da Costa Negreiros do Valle, Rodrigo Medeiros de Souza, Elisabeth Níglio de Figueiredo, Mônica Taminato, Dayana Souza Fram Revista Brasileira de Enfermagem.2019; 72(5): 1265. CrossRef
High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load Tai-Chung Tseng, Chun-Jen Liu, Chen-Yang Hsu, Chun-Ming Hong, Tung-Hung Su, Wan-Ting Yang, Chi-Ling Chen, Hung-Chih Yang, Yen-Tsung Huang, Stephanie Fang-Tzu Kuo, Chen-Hua Liu, Pei-Jer Chen, Ding-Shinn Chen, Jia-Horng Kao Gastroenterology.2019; 157(6): 1518. CrossRef
Nucleos(t)ide analogues in patients with chronic hepatitis B: to stop or not to stop? Jia-Horng Kao, Thomas Berg Gut.2019; 68(12): 2105. CrossRef
Non‐invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low‐level viremia Namyoung Paik, Dong H. Sinn, Ji H. Lee, In S. Oh, Jung H. Kim, Wonseok Kang, Geum‐Youn Gwak, Yong‐Han Paik, Moon S. Choi, Joon H. Lee, Kwang C. Koh, Seung W. Paik Liver International.2018; 38(1): 68. CrossRef
Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy Meng-Lan Wang, Juan Liao, Bing Wei, Dong-Mei Zhang, Ming He, Ming-Chuan Tao, En-Qiang Chen, Hong Tang Infectious Diseases.2018; 50(7): 522. CrossRef
Three types of preS1 start codon deletion variants in the natural course of chronic hepatitis B infection Won Hyeok Choe, Hong Kim, So‐Young Lee, Yu‐Min Choi, So Young Kwon, Hee Won Moon, Mina Hur, Bum‐Joon Kim Journal of Gastroenterology and Hepatology.2018; 33(7): 1370. CrossRef
High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B Gi-Ae Kim, Young-Suk Lim, Seungbong Han, Jonggi Choi, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee Gut.2018; 67(5): 945. CrossRef
Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? Elia Moreno-Cubero, Robert T Sánchez del Arco, Julia Peña-Asensio, Eduardo Sanz de Villalobos, Joaquín Míquel, Juan Ramón Larrubia World Journal of Gastroenterology.2018; 24(17): 1825. CrossRef
Global HBV burden: guesstimates and facts Dina Ginzberg, Robert J. Wong, Robert Gish Hepatology International.2018; 12(4): 315. CrossRef
Hepatitis B: From control to cure Jia-Horng Kao Journal of the Formosan Medical Association.2018; 117(10): 868. CrossRef
HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis Bhawna Poonia, Natarajan Ayithan, Madhuparna Nandi, Henry Masur, Shyam Kottilil Scientific Reports.2018;[Epub] CrossRef
Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace Chih-Lin Lin, Jia-Horng Kao Hepatology International.2017; 11(1): 31. CrossRef
Unmet Needs in Clinical and Basic Hepatitis B Virus Research Tung-Hung Su, Jia-Horng Kao The Journal of Infectious Diseases.2017; 216(suppl_8): S750. CrossRef
Quantitative Hepatitis B Surface Antigen in Different Phases of Chronic HBV Infection in Vietnamese Patients: The Preliminary Study Huong Nguyen, Hang Le, Nhu Bao, Salma Fala, Ibrahim Radwan, Huy Nguyen, Hoa Pham MedPharmRes.2017; 1(1): 2. CrossRef
First
Prev
